Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves

References

• Holah NS, El-Azab DS, Aiad HA, Sweed DM. Hepatocellular carcinoma in Egypt: epidemiological and histopathological properties. Menoufia Med J. 2015;28:718–724.
   Google Scholar
• Tanimoto Y, Tashiro H, Aikata H, et al. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 2012;19(2):418–425. doi:10.1245/s10434-011-1866-121710324
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. High Rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726. doi:10.1016/j.jhep.2016.04.00827084592
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. Tumor recurrence after interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumor growth. J Hepatol. 2017;66:S20. doi:10.1016/S0168-8278(17)30302-1
   Web of Science ®Google Scholar
• El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected egyptian cohort: a comparative analysis. J Viral Hepat. 2018;25(6):623–630. doi:10.1111/jvh.2018.25.issue-629274197
   PubMed Web of Science ®Google Scholar
• Cheng Z, Yang P, Qu S, et al. Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection. Hpb J. 2015;17:422–427. doi:10.1111/hpb.12367
   PubMed Web of Science ®Google Scholar
• Arnaoutakis D, Mavros M, Shen F, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol. 2014;21(1):147–154. doi:10.1245/s10434-013-3211-323959056
   PubMed Web of Science ®Google Scholar
• Imai Y, Tamura S, Tanaka H, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2010;17(3):185–191. doi:10.1111/jvh.2010.17.issue-319709362
   PubMed Web of Science ®Google Scholar
• Xu C, Luo L, Yu Y, et al. Screening therapeutic targets of ribavirin in hepatocellular carcinoma. Oncol Lett. 2018;15(6):9625–9632. doi:10.3892/ol.2018.855229805683
   PubMed Web of Science ®Google Scholar
• Hiroaki H, Nouso K, Kobayashi Y, et al. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol. 2011;16(3):210–220.21152943
   PubMed Web of Science ®Google Scholar
• Shuhei N, Akihiro T, Shoji K.Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48(1):71–75. doi:10.1159/00008209815785093
   PubMed Web of Science ®Google Scholar
• Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after Curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17(4):287–292. doi:10.1111/jvh.2010.17.issue-419732321
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–181. doi:10.7326/0003-4819-131-3-199908030-0000310428733
   PubMed Web of Science ®Google Scholar
• Takeaki S, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res. 2001;20(3):301–311. doi:10.1016/S1386-6346(00)00148-011404190
   PubMed Web of Science ®Google Scholar
• Naoya K, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30(7):1197–1204. doi:10.1111/jgh.1292525682720
   PubMed Web of Science ®Google Scholar
• Cheol JS, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol. 2013;13(40):5343–5350.
   Google Scholar
• El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCVinfection. Hepatology. 2016;64:130–137. doi:10.1002/hep.2853526946190
   PubMed Web of Science ®Google Scholar
• Kensaku S, Kayashima H, Iguchi T, et al. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol. 2009;99(1):32–37. doi:10.1002/jso.2117618985618
   PubMed Web of Science ®Google Scholar
• Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Res. 2015;6(3):301–310. doi:10.1016/j.jare.2014.11.00426257927
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15(12):1643–1652. doi:10.1080/14740338.2017.124078127661100
   PubMed Web of Science ®Google Scholar
• Reig M, Boix L, Mariño Z, Torres F, Forns X, Bruix J. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin Liver Dis. 2017;37:109–118. doi:10.1055/s-0037-160134928388736
   PubMed Web of Science ®Google Scholar
• Conti F, Federica B, Alessandra S, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733. doi:10.1016/j.jhep.2016.06.01527349488
   PubMed Web of Science ®Google Scholar
• Kolly P, Waidmann O, Vermehren J, et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multicentre study. J Hepatol. 2017;67:876–878. doi:10.1016/j.jhep.2017.07.00728733219
   PubMed Web of Science ®Google Scholar
• Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65(4):859–860. doi:10.1016/j.jhep.2016.06.02327392425
   PubMed Web of Science ®Google Scholar
• Granata R, Di Costanzo G, Sanduzzi Zamparelli M, et al. Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience. Digestive Liver Dis 2017;49(1):e45–46. doi:10.1016/j.dld.2017.01.094
   Web of Science ®Google Scholar
• Victor V, Pradat P, Hartig-Lavie K, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int. 2017;37(8):1122–1127. doi:10.1111/liv.1345628423231
   PubMed Web of Science ®Google Scholar
• Hiroko N, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(5):933–939. doi:10.1016/j.jhep.2017.05.02828627363
   PubMed Web of Science ®Google Scholar
• Ikeda K, Yusuke K, Masahiro K, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62(10):2932–2942. doi:10.1007/s10620-017-4739-z28884320
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Alimenti E, Biganzoli E. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy. Hepatology. 2017;66(Supplement 1 PG–734A–735A):734A–735A.
   Google Scholar
• Cabibbo G, Petta S, Calvaruso V, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46(7):688–695. doi:10.1111/apt.1425628791711
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Nomura H, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018;47(1):104–113. doi:10.1111/apt.1438029035002
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2013;58(3):495–501. doi:10.1016/j.jhep.2012.10.01723099187
   PubMed Web of Science ®Google Scholar
• Mashiba T, Kouji J, Masayuki K, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 2018;13(4):1–13. doi:10.1371/journal.pone.0194704
   Web of Science ®Google Scholar
• ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts) Electronic address: [email protected]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65::734–740. doi:10.1016/j.jhep.2016.05.04527288051
   PubMed Web of Science ®Google Scholar
• Waziry R, Behzad H, Jason G, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review. J Hepatol. 2017;67(6):1204–1212. doi:10.1016/j.jhep.2017.07.02528802876
   PubMed Web of Science ®Google Scholar
• Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48(2):127–137. doi:10.1111/apt.1482329851093
   PubMed Web of Science ®Google Scholar
• Renzulli M, Buonfiglioli F, Conti F, et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol. 2018;28:506–513. doi:10.1007/s00330-017-5033-328894901
   PubMed Web of Science ®Google Scholar
• Faillaci F, Luca M, Rosina C, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology. 2018;68(3):1010–1024. doi:10.1002/hep.2991129604220
   PubMed Web of Science ®Google Scholar
• Adhoute X, Guillaume P, Jean Luc R, et al. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30(4):368–375. doi:10.1097/MEG.000000000000108229384796
   PubMed Web of Science ®Google Scholar
• Minami T, Ryosuke T, Ryo N, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65(6):1272–1273. doi:10.1016/j.jhep.2016.07.04327524465
   PubMed Web of Science ®Google Scholar
• Petta S, Cabibbo G, Barbara M, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther. 2017;45(1):160–168. doi:10.1111/apt.1382127790734
   PubMed Web of Science ®Google Scholar
• Zhou D, Yaqin W, Wen Z, Lu C, Jiajie L. WFA(+) -M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases. Liver Int. 2016;36:612. doi:10.1111/liv.1302426583749
   PubMed Web of Science ®Google Scholar
• Yasui Y, Masayuki K, Yasuyuki K, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res. 2018;48(13):1131–1139. doi:10.1111/hepr.1323330030872
   PubMed Web of Science ®Google Scholar
• Kanda T, Matsuoka S, Moriyama M. Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. Hepatol Int. 2018;12:90–93. doi:10.1007/s12072-018-9862-129619621
   PubMed Web of Science ®Google Scholar
• Pasquali S, Mocellin S. The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem. 2010;17:3327–3336. doi:10.2174/09298671079317639320712571
   PubMed Web of Science ®Google Scholar
• Chu PS, Nakamoto N, Taniki N, et al. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS One. 2017;12:e0179096. doi:10.1371/journal.pone.017909628617830
   PubMed Web of Science ®Google Scholar
• Debes JD, van Tilborg M, Groothuismink ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515–517.e. doi:10.1053/j.gastro.2017.10.03529102620
   PubMed Web of Science ®Google Scholar
• Villani R, Facciorusso A, Bellanti F, et al. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS One. 2016;11:e0167934. doi:10.1371/journal.pone.016793427997563
   PubMed Web of Science ®Google Scholar
• Waring JF, Dumas EO, Abel S, et al. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. J Viral Hepat. 2016;23:96–104. doi:10.1111/jvh.1247026436610
   PubMed Web of Science ®Google Scholar
• Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014;49:589–593. doi:10.1007/s00535-014-0932-424531873
   PubMed Web of Science ®Google Scholar
• Liu CH, Kao JH. Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction? Transl Cancer Res. 2016;5:S192–195. doi:10.21037/tcr.2016.07.32
   Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982. doi:10.1056/NEJMoa140286924725237
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post liver transplantation recurrence. Hepatology. 2016;63:1493–1505. doi:10.1002/hep.v63.526754432
   PubMed Web of Science ®Google Scholar
• Waziry R, Grebely J, Amin J, et al. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). J Hepatol. 2016;65:1086–1093. doi:10.1016/j.jhep.2016.08.01027569777
   PubMed Web of Science ®Google Scholar
• Mancebo A, González-Diéguez ML, Navascués CA, et al. Adherence to a semiannual surveillance program for hepatocellular carcinoma in patients with liver cirrhosis. J Clin Gastroenterol. 2017;51:557–563. doi:10.1097/MCG.000000000000073427775957
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. doi:10.1002/hep.2419921374666
   PubMed Web of Science ®Google Scholar
• Nault J-C, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65:663–665. doi:10.1016/j.jhep.2016.07.00427417216
   PubMed Web of Science ®Google Scholar
• Marubashi S, Sakon M. ‘‘Local recurrence” is not equal to ‘‘Local dissemination” after resection for hepatocellular carcinoma. J Hepatol. 2016;65:1061. doi:10.1016/j.jhep.2016.06.03027453464
   PubMed Web of Science ®Google Scholar
• Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016;23:994–1002. doi:10.1111/jvh.1257827500382
   PubMed Web of Science ®Google Scholar